HS-10529

Other Medications

Description

HS-10529 is an experimental drug currently being studied in clinical trials. It is being investigated as a potential treatment for advanced solid tumors, including colorectal cancer, specifically in patients whose tumors have a KRAS G12D mutation. This is a specific type of change (mutation) in the KRAS gene. The drug is in Phase 1 trials, which means the main goal is to determine the safest dose and see if it causes any side effects. Researchers are also looking for early signs that the drug might be effective. HS-10529 is being developed by Jiangsu Hansoh Pharmaceutical Co., Ltd.

Mechanism of Action

HS-10529 is being studied to see if it can target cancer cells. The specific way it works (its mechanism of action) is still being investigated in clinical trials. It is designed for patients with advanced solid tumors that have a specific KRAS G12D mutation.

Side Effects

Because HS-10529 is an experimental drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of Phase 1 trials is to assess safety and tolerability. Information about specific side effects observed in the trials is not yet widely available But as with many cancer drugs Potential side effects could include fatigue Nausea Changes in blood counts And other reactions. More information will become available as the trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06963398 Phase 1

Not yet recruiting

A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

Quick Info

Category	Other Medications
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.